18 publications
| Name | Date | Type | Actions |
|---|---|---|---|
2010 annual earnings Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements. |
04/04/2011 | Public releases | |
2010 Revenues grow 11.8%, driven by organic growth The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth. |
25/01/2011 | Public releases | |
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
23/03/2023 | Public releases | |
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases | |
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
18/01/2023 | Public releases | |
Availability of the 2022 universal registration document On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
13/04/2023 | Public releases | |
European launch of new Nsaid Cimalgex® Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs. |
14/06/2011 | Public releases | |
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
29/09/2011 | Public releases | |
International expansion and new product launches Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011. |
19/07/2011 | Public releases | |
Jacques du Puy appointed Vétoquinol Managing Director Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment |
12/10/2011 | Public releases |